These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 28565742)
1. [Sorafenib in combination with chemotherapy as first-line therapy for FLT3-ITD positive acute myeloid leukemia]. Zhang QY; Wei XD; Yin QS; Mi RH; Yuan FF; Chen L Zhonghua Xue Ye Xue Za Zhi; 2017 May; 38(5):415-420. PubMed ID: 28565742 [No Abstract] [Full Text] [Related]
2. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib]. Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618 [TBL] [Abstract][Full Text] [Related]
3. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197 [TBL] [Abstract][Full Text] [Related]
5. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world]. Jia JS; Zhu HH; Gong LZ; Zhao T; Wang J; Jiang Q; Huang XJ; Jiang H Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):398-403. PubMed ID: 31207705 [No Abstract] [Full Text] [Related]
6. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3. Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501 [TBL] [Abstract][Full Text] [Related]
7. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Brunner AM; Li S; Fathi AT; Wadleigh M; Ho VT; Collier K; Connolly C; Ballen KK; Cutler CS; Dey BR; El-Jawahri A; Nikiforow S; McAfee SL; Koreth J; Deangelo DJ; Alyea EP; Antin JH; Spitzer TR; Stone RM; Soiffer RJ; Chen YB Br J Haematol; 2016 Nov; 175(3):496-504. PubMed ID: 27434660 [TBL] [Abstract][Full Text] [Related]
8. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516 [TBL] [Abstract][Full Text] [Related]
9. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323 [TBL] [Abstract][Full Text] [Related]
10. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172 [TBL] [Abstract][Full Text] [Related]
11. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500 [TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Lam SS; Ho ES; He BL; Wong WW; Cher CY; Ng NK; Man CH; Gill H; Cheung AM; Ip HW; So CC; Tamburini J; So CW; Ho DN; Au CH; Chan TL; Ma ES; Liang R; Kwong YL; Leung AY Sci Transl Med; 2016 Oct; 8(359):359ra129. PubMed ID: 27708062 [TBL] [Abstract][Full Text] [Related]
13. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of Sorafenib as monotherapy to FLT3-ITD positive acute myeloid leukemia]. Jia JS; Zhu HH; Fu HX; Gong LZ; Kong J; Huang XJ; Jiang H Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1022-1026. PubMed ID: 28088962 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Yalniz F; Abou Dalle I; Kantarjian H; Borthakur G; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Sasaki K; Daver N; DiNardo C; Pemmaraju N; Short NJ; Yilmaz M; Bose P; Naqvi K; Pierce S; Nogueras González GM; Konopleva M; Andreeff M; Cortes J; Ravandi F Am J Hematol; 2019 Sep; 94(9):984-991. PubMed ID: 31237017 [TBL] [Abstract][Full Text] [Related]
18. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140 [TBL] [Abstract][Full Text] [Related]
19. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation]. Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933 [No Abstract] [Full Text] [Related]
20. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]